利用颅内磁刺激测量和操纵人体运动系统中功能特定的神经通路

Executive Industry Relevance

Establishing causal links between neural circuit activity and behavioral outcomes is critical for de-risking target validation in neuropsychiatric drug development. Transcranial magnetic stimulation (TMS) enables direct, non-invasive manipulation of functionally specific pathways, providing mechanistic insights that bridge preclinical models and human physiology. This approach supports predictive confidence in target engagement and circuit-based therapeutic strategies for neurological and psychiatric disorders.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogates causal contributions of cortico-cortical interactions to motor and cognitive function, enabling hypothesis testing of neural targets.
• Operational Value: Provides reproducible, quantitative readouts of pathway modulation via motor-evoked potential (MEP) amplitude changes.
• Predictive Value: Supports target de-risking by demonstrating reversible, bidirectional control of synaptic efficiency in interconnected brain regions.

Screening & Assay Development

• Scientific Value: Enables standardized assessment of functional connectivity between motor and non-motor cortical areas under defined task contexts.
• Operational Value: Dual-site TMS protocols yield quantifiable, time-resolved measures of synaptic plasticity suitable for assay optimization.
• Assay Readiness: Facilitates preparation of validated human neural systems for downstream compound screening targeting circuit-level phenotypes.

Translational & Preclinical Research

• Translational Value: Cortico-cortical interaction profiles derived from TMS can inform disease-relevant models of circuit dysfunction in psychiatric and neurological conditions.
• Mechanistic De-risking: Demonstrates how repeated paired stimulation induces lasting plasticity, supporting biomarker development for target engagement.
• Continuity of Evidence: Links acute physiological effects (MEP modulation) to longer-term plasticity, aligning with preclinical-to-clinical translation pathways.

Pipeline & Workflow Integration

The method integrates into discovery workflows by enabling causal interrogation of neural circuits prior to lead identification, with outputs informing target selection and mechanistic validation.

• Discovery Biology: Supports hypothesis-driven testing of causal relationships between cortical areas and motor output, reducing ambiguity in target validation.
• Screening: Generates standardized, quantitative MEP-based readouts that reflect changes in synaptic efficacy, enabling reliable compound effect assessment.
• Analytics: Provides time-course data on plasticity induction and normalization of evoked responses, facilitating quantitative comparison across conditions.
• Translational Research: Connects acute TMS-induced changes to lasting after-effects, supporting alignment with preclinical models of circuit-based therapeutics.
• Enterprise Reuse: Dual-site TMS protocols can be standardized across sites and adapted to different cortical targets, promoting reusable platform capabilities.

Operational & Enterprise Impact

• Scientific Value: Enables causal dissection of neural pathways, increasing confidence in target mechanism and reducing false positives in target validation.
• Operational Value: Standardized neuro-navigation and thresholding procedures ensure reproducibility across laboratories and experimental sessions.
• Strategic Value: Informs go/no-go decisions by providing human-relevant, circuit-level data on target modulation and behavioral relevance.
• Portfolio Impact: Supports risk-adjusted prioritization of targets based on demonstrated capacity for bidirectional, plasticity-inducing modulation of neural pathways.

Implementation Considerations

• Expertise in neuro-navigation, TMS safety protocols, and EMG signal acquisition is required for accurate coil placement and threshold determination.
• Dual TMS stimulators, figure-eight coils, EMG acquisition systems, and MRI-compatible navigation infrastructure are essential for implementation.
• Standardization of interstimulus intervals, stimulus intensities, and trial timing across operators and sites is critical for data comparability.
• Adaptation to different cortical targets requires individualized localization and thresholding based on subject-specific anatomy and motor maps.
• Practical limitations include inter-individual variability in cortical excitability and the need for careful screening to exclude TMS contraindications.

Biopharma FAQs